

Attorney Docket No.: PB60642

Customer No. 20462

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	LUO et al.	Confirmation No. 8806
Serial No.:	10/596,648	Group Art Unit: 1624
Filed:	May 29, 2007	Examiner: Susanna Moore
For:	CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO	

Commissioner for Patents
Alexandria, Va 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Laura K. Madden
Agent for Applicants
Registration No.48,352

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5044
Facsimile (610) 270-5090